A Study of Apatinib in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01270386
Recruitment Status : Completed
First Posted : January 5, 2011
Last Update Posted : February 10, 2012
Sun Yat-sen University
Information provided by:
Jiangsu HengRui Medicine Co., Ltd.

Brief Summary:
Apatinib is a tyrosin-inhibitor agent targeting at vascular endothelial growth factor receptor (VEGFR), and it's anti-angiogenesis effect has been viewed in preclinical tests. Phase I study has shown that the drug's toxicity is manageable and the maximum tolerable daily dose is 850 mg. The purpose of this study is to determine whether apatinib can improve progression free survival compared with placebo in patients with advanced non-squamous and non-small cell lung cancer who failed two lines of chemotherapy.

Condition or disease Intervention/treatment Phase
Non-Small-Cell Lung Cancer Drug: apatinib Drug: placebo Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 136 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Placebo-controlled, Double-blind, Multicenter, Phase II Study of Apatinib as Third Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer
Study Start Date : March 2010
Actual Primary Completion Date : July 2011
Actual Study Completion Date : September 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Apatinib
Apatinib 750 mg qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
Drug: apatinib
Apatinib 750 mg p.o. once daily
Placebo Comparator: Placebo
Placebo qd p.o., and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
Drug: placebo
placebo p.o. once daily

Primary Outcome Measures :
  1. Progression free survival [ Time Frame: 8 weeks ]

Secondary Outcome Measures :
  1. Overall Survival safety [ Time Frame: 8 weeks ]
  2. DCR(Disease control rate) [ Time Frame: 8 weeks ]
  3. ORR(objective response rate) [ Time Frame: 8 weeks ]
  4. QoL(quality of life) [ Time Frame: 8 weeks ]
  5. Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: 8 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • ≥ 18 and ≤ 70 years of age
  • Histologically or cytologic confirmed advanced non-squamous and non-small cell lung cancer.
  • At least one measurable lesion which has not received radiotherapy (larger than 10 mm in diameter by spiral CT scan)
  • Have failed for 2 lines of chemotherapy including EGFR-TKI.
  • ECOG performance scale 0 - 1.
  • Life expectancy of more than 3 months.
  • Duration from the last therapy is more than 6 weeks for nitroso or mitomycin
  • More than 4 weeks after operation or radiotherapy
  • More than 4 weeks for cytotoxic agents or tyrosine kinase inhibitors inhibitors
  • Adequate hepatic, renal, heart, and hematologic functions (hemoglobin ≥ 90g/L, platelets ≥ 80×10^9/L, neutrophils ≥ 1.5×10^9/L, total bilirubin within 1.25×the upper limit of normal(ULN), and serum transaminase≤2.5×the ULN (If liver metastases, serum transaminase≤5×the ULN), serum creatine ≤ 1.5 x ULN, creatinine clearance rate ≥ 50ml/min,
  • signed and dated informed consent.Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure.

Exclusion Criteria:

  • Squamous cell carcinoma (including adenosquamous carcinoma, undifferentiated carcinoma); small cell lung cancer (including small cell and non-small cell mixed lung cancer)
  • Pregnant or breastfeeding women
  • Intercurrence with one of the following: hypertension, coronary artery disease, arrhythmia and heart failure
  • Any factors that influence the usage of oral administration
  • PT, APTT, TT, Fbg abnormal, Receiving the therapy of thrombolysis or anticoagulation.
  • Within 4 weeks before the first use of drugs, occurs pulmonary hemorrhage (≥ CTCAE class 2) or other parts' hemorrhage (≥ CTCAE class 3).
  • Long-term untreated wounds or fractures.
  • Within 6 months before the first treatment occurs artery / venous thromboembolic events, such as cerebral vascular accident (including transient ischemic attack), deep vein thrombosis and pulmonary embolism, etc.
  • Application of anticoagulants or vitamin K antagonists such as warfarin, heparin or its analogues; If the prothrombin time international normalized ratio (INR) ≤ 1.5, with the purpose of prevention, the use of small doses of warfarin (1mg orally, once daily) or low-dose aspirin (between 80mg to 100mg daily) is allowed.
  • Abuse of alcohol or drugs
  • Less than 4 weeks from the last clinical trial
  • Treatment with VEGFR, PDGFR, sSRC-TKI before.
  • History of any second malignancies within 3 years except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01270386

China, Guangdong
Department of Medical Oncology, Cancer Center, Sun Yet-sen University
Guangzhou, Guangdong, China, 510060
Sponsors and Collaborators
Jiangsu HengRui Medicine Co., Ltd.
Sun Yat-sen University
Principal Investigator: Li Zhang, Dr Sun Yat-sen University

Responsible Party: Li Zhang, Department of Medical Oncology, Cancer Center, Sun Yet Sen University Identifier: NCT01270386     History of Changes
Other Study ID Numbers: HENGRUI 20101219
First Posted: January 5, 2011    Key Record Dates
Last Update Posted: February 10, 2012
Last Verified: February 2012

Keywords provided by Jiangsu HengRui Medicine Co., Ltd.:
phase II

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms